July 24, 2026

FDA Approves Ophthalmic Bevacizumab

The approval establishes the first and only FDA-approved ophthalmic formulation of bevacizumab for neovascular age-related macular degeneration in the US.

MDSpire News

June 29, 2026

FDA Approves New Treatment for Thyroid Eye Disease

Phase 3 THRIVE and THRIVE-2 trials supported approval following improvements in proptosis and diplopia in active and chronic disease.

MDSpire News

May 29, 2026

FDA Monthly Preview: Key June Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

MDSpire News

April 29, 2026

FDA Monthly Preview: Key May Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

MDSpire News

April 20, 2026

Dual-Agent Eye Drop for Presbyopia

YUVEZZI™ approved for the treatment of presbyopia, blurry close-up vision due to aging

The Ophthalmologist

March 26, 2026

St. Louis Pediatrician Gets 20-Year Sentence

A physician exploited patients with addiction for nearly a decade, trading prescriptions for sex acts, photos, and cash

MDSpire News

March 23, 2026

FDA Approves TECNIS PureSee IOL for Cataract Surgery

First FDA-approved extended depth of focus (EDOF) IOL maintaining contrast sensitivity comparable to an aspheric monofocal IOL

The Ophthalmologist

March 12, 2026

Cataract Surgeons Gain a New Lens Tool

An extended depth of focus intraocular lens approved by the FDA is designed to improve visual range while maintaining contrast sensitivity in cataract surgery.

MDSpire News

February 25, 2026

FDA Approves First Therapy for Allergic Fungal Rhinosinusitis

Patients with allergic fungal rhinosinusitis now have a targeted biologic option.

MDSpire News

January 14, 2026

FDA Clears Rayner's Sophi Phaco System

The company said that surgeons and clinical teams can benefit from faster setup, quicker patient turnover, and greater mobility.

Ophthalmology Management